Search Results

You are looking at 81 - 90 of 299 items for :

Clear All
Full access

Severe Hypertriglyceridemia and Acute Pancreatitis Expiration Date: 1/11/14 NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2013 Expiration Date: 1/11/14 Modern Staging of Small Cell Lung Cancer Expiration Date: 1/11/14 CASE REPORT

Full access

11 11 1 1 5 5 9 9 jnccn0110005 10.6004/jnccn.2013.0003 Multiple Myeloma, Version 1.2013 Anderson Kenneth C. 1 MD Alsina Melissa 2 MD Bensinger William 3 MD Biermann J. Sybil 4 MD Cohen Adam D. 5 MD Devine Steven 6

Full access

Young Adults; Chronic Myelogenous Leukemia; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; Lung Cancer Screening; and Soft Tissue Sarcoma. NCCN is committed to developing a comprehensive patient library with support from the NCCN

Full access

Jason Gotlib and Peter L. Greenberg

. Crit Rev Immunol. 2002 ; 22 : 425 – 437 . 2 Anderson KC . Novel biologically based therapies for myeloma . Cancer J. 2001 ; 7 ( Suppl 1 ): S19 – S23 . 3 Alvi S Borok RZ Shaher A . Thalidomide significantly modifies bone

Full access

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg and Shayna Sarosiek

hypercalcemia of malignancy and are part of guideline-directed therapy for patients with multiple myeloma. 7 , 8 In certain patient populations, BMAs can improve pain control, quality of life, and overall survival. 9 , 10 Despite the advantages of BMA

Full access

Provided the First Russian Translation of the NCCN Guidelines for Patients on Treating Multiple Myeloma When a person is diagnosed with cancer, they immediately start looking for information about their diagnosis. However, it is easy to get lost in the

Full access

Pamela S. Becker

in the laboratory and in human subjects, and is now FDA-approved as plerixafor for stem cell mobilization in non-Hodgkin’s lymphoma (NHL) and multiple myeloma. Several agents have been shown to mobilize stem cells in the laboratory, including

Full access

Alok A. Khorana

and CONKO-004, included only patients with pancreas cancer 13 - 15 and the PRODIGE trial included only patients with malignant glioma. 16 Two additional studies evaluated thromboprophylaxis specifically in multiple myeloma. 17 , 18 Mixed Solid

Full access

Comprehensive Review of the Use of JAK2 Inhibitors Friday, February 23, 2018 • 4:30–5:30 PM EST Stephen J. Harnicar, PharmD, BCOP, BCPS, Memorial Sloan Kettering Cancer Center Integrating New Treatment Options for Multiple Myeloma: Focus on Oral

Full access

, visit NCCN.org . NCCN Releases New Translations of NCCN Guidelines NCCN recently posted new translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin’s Lymphomas, and